Insomnia Treatment Market to Reach $4.85 Billion by 2035

The global insomnia treatment market was valued at $3.10 billion in 2025 and is projected to reach $4.85 billion by 2035, growing at a CAGR of 4.6% during the forecast period (2026–2035). The increasing prevalence of sleep disorders driven by rising stress levels, mental health conditions, and lifestyle changes is a major factor supporting market growth. According to the World Health Organization, approximately 1 in 8 people globally live with a mental disorder, which significantly contributes to insomnia incidence. Insomnia treatment solutions, including pharmacological therapies and digital cognitive behavioural therapy (CBT-I), play a critical role in improving sleep quality, reducing long-term health risks, and enhancing patient outcomes. The market is witnessing steady adoption of orexin receptor antagonists and digital therapeutics as healthcare providers shift toward targeted and non-invasive treatment approaches.

Browse the full report description of “Insomnia Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Pharmacological Treatment, Non-Pharmacological Treatment), By Drug Class (Benzodiazepines, Non-benzodiazepine Hypnotics, Orexin Receptor Antagonists, Antidepressants, Melatonin Receptor Agonists), By Therapy Type (Cognitive Behavioural Therapy (CBT-I), Sleep Hygiene Education Programs, Relaxation Techniques & Mindfulness Therapy, Digital Therapeutics / App-based Sleep Programs), By End Users (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct-to-Consumer Digital Platforms), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/insomnia-treatment-market

Pharmacological treatments continue to dominate the market, particularly benzodiazepines and non-benzodiazepine hypnotics, while non-pharmacological therapies such as CBT-I are gaining traction due to increasing awareness of long-term dependency risks associated with sleep medications. Hospital and retail pharmacies remain the primary distribution channels, while online pharmacies and direct-to-consumer digital platforms are expanding access to insomnia therapies. The growing geriatric population and increasing diagnosis rates are further supporting demand across both developed and emerging healthcare systems.

Europe Mental Health Burden and Sleep Disorder Trends
In Europe, rising mental health challenges are directly contributing to insomnia prevalence. According to the Organisation for Economic Co-operation and Development, mental health conditions account for over 5% of GDP in healthcare and social costs across European countries. Additionally, increasing workplace stress and aging populations are accelerating the demand for insomnia treatment solutions. As a result, healthcare systems are expanding access to behavioural therapies and prescription treatments, driving adoption of both pharmacological and non-pharmacological interventions across the region.

US Healthcare Utilization and Sleep Disorder Diagnosis Growth
In the United States, growing awareness and diagnosis of sleep disorders are significantly supporting market expansion. The U.S. Food and Drug Administration continues to approve advanced insomnia therapies, including orexin receptor antagonists, to address unmet clinical needs. Furthermore, increasing healthcare expenditure and improved access to telehealth services are enabling broader adoption of digital therapeutics such as CBT-I programs. These trends are encouraging pharmaceutical companies to invest in innovative drug development and digital health solutions, strengthening market growth.

Innovation Leaders Transforming the Insomnia Treatment Market
The key players in the insomnia treatment market include Eisai Co., Ltd., Idorsia Pharmaceuticals Ltd., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Vanda Pharmaceuticals Inc., among others. These companies are focusing on developing advanced therapies such as dual orexin receptor antagonists, improving drug safety profiles, and expanding digital therapeutic offerings. Continuous innovation in targeted therapies and personalized treatment approaches is enhancing patient adherence and treatment effectiveness across global healthcare systems.

• In September 2025, Idorsia Pharmaceuticals Ltd. launched QUVIVIQ® (daridorexant) in China in collaboration with Simcere Pharmaceuticals, expanding its global footprint in the insomnia treatment market. The drug, a dual orexin receptor antagonist, offers a targeted mechanism of action with reduced risk of dependency and next-day drowsiness compared to traditional therapies. This launch strengthens Idorsia’s position in Asia-Pacific and addresses the growing demand for safer and effective insomnia treatments in China.
• In August 2025, Eisai Co., Ltd. launched DAYVIGO® (lemborexant) in China following regulatory approval, marking the first orexin receptor antagonist introduced in the country for insomnia treatment. The drug targets sleep onset and maintenance disorders through a novel mechanism, strengthening Eisai’s presence in the Asia-Pacific market and expanding access to advanced insomnia therapies.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Treatment Type
• Drug Class
• Therapy Type
• End Users
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape - Eisai Co., Ltd., Idorsia Pharmaceuticals Ltd., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Vanda Pharmaceuticals Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Insomnia Treatment Market Report Segment

By Treatment Type

• Pharmacological Treatment
• Non-Pharmacological Treatment

By Drug Class

• Benzodiazepines
• Non-benzodiazepine Hypnotics
• Orexin Receptor Antagonists
• Antidepressants
• Melatonin Receptor Agonists

By Therapy Type

• Cognitive Behavioural Therapy (CBT-I)
• Sleep Hygiene Education Programs
• Relaxation Techniques & Mindfulness Therapy
• Digital Therapeutics / App-based Sleep Programs

By End Users

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Direct-to-Consumer Digital Platforms

Global Insomnia Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/insomnia-treatment-market